Full text is available at the source.
Abstract
Substantial interindividual variability in treatment response to glucagon-like peptide-1 receptor agonists (GLP-1RAs) is a defining clinical challenge.
- GLP-1RAs and dual GLP-1/GIP receptor agonists are effective for managing type 2 diabetes and obesity.
- Despite their effectiveness, patients experience varying responses to these treatments.
- Understanding the factors contributing to this variability may enhance personalized treatment strategies.
Simplified